
CryptoMedix LLC: A biotech firm specializing in therapeutic product discovery and development.
CryptoMedix LLC, founded with a mission to revolutionize cancer treatment, focuses on the discovery, clinical development, and commercialization of therapeutic products. The company specializes in immuno-oncology, particularly targeting the tumor microenvironment (TME). Their core technology platform involves first-in-class therapeutic antibodies designed to promote the migration and activation of immune cells within tumors, aiming to enhance the body's natural ability to fight cancer.
Notable figures affiliated with CryptoMedix include its founders and key scientific advisors who are experts in biotechnology and oncology. The company has garnered attention and support from prominent investors in the biotech sector. Despite the challenges posed by the COVID-19 pandemic, CryptoMedix has made significant scientific advancements, positioning itself as a leader in the immuno-oncology space. Their innovative approach has the potential to significantly impact cancer treatment outcomes, marking a promising future for both patients and the biotech industry.

Meditope Biosciences
meditope.com

Cybrexa
cybrexa.com

Camino Pharma
caminopharma.com

Intellimedix

BioEclipse Therapeutics
bioeclipse.com

Ceramedix Holding
ceramedix.com

CryoMedix
cryomedix.com

OmniCyte
omnicyte.com

OncoResponse

CorMedix
cormedix.com

NextCure
nextcure.com

Curie.Bio
curie.bio

Nano Cures
nanocures.com

Immune-Onc Therapeutics
immuneonc.com

Parthenon Therapeutics
parthenontx.com
Companies similar to CryptoMedix include Meditope Biosciences, Cybrexa, Camino Pharma and Intellimedix.
CryptoMedix was founded in 2013.
CryptoMedix's headquarters is located in Harpswell, ME, US.
CryptoMedix's most recent funding round was for $276.5k (USD) in June 2016.
As of Jun 8, 2016, CryptoMedix has raised a total of $276.5k (USD).
CryptoMedix has 30 employees as of Feb 5, 2024.